Latest & greatest articles for anticoagulation

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on anticoagulation or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on anticoagulation and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for anticoagulation

1. Andexanet alfa (Ondexxya) - For adult patients treated with a direct factor Xa (FXa) inhibitor (apixaban or rivaroxaban) when reversal of anticoagulation is needed due to life-threatening or uncontrolled bleeding.

Andexanet alfa (Ondexxya) - For adult patients treated with a direct factor Xa (FXa) inhibitor (apixaban or rivaroxaban) when reversal of anticoagulation is needed due to life-threatening or uncontrolled bleeding. 1 Published 7 September 2020 1 SMC2273 andexanet alfa 200 mg powder for solution for infusion (Ondexxya®) Portola Pharmaceuticals UK Ltd. 07 August 2020 The Scottish Medicines Consortium (SMC) has completed its assessment of the above product and, following review by the SMC executive (...) , advises NHS Boards and Area Drug and Therapeutics Committees on its use in NHSScotland. The advice is summarised as follows: ADVICE: following a full submission andexanet alfa (Ondexxya®) is accepted for use within NHSScotland on an interim basis subject to ongoing evaluation and future reassessment. Indication under review: For adult patients treated with a direct factor Xa (FXa) inhibitor (apixaban or rivaroxaban) when reversal of anticoagulation is needed due to life-threatening or uncontrolled

2020 Scottish Medicines Consortium

2. Recurrent venous thromboembolism during anticoagulation with edoxaban or warfarin: A post hoc analysis of the Hokusai-VTE trial

Recurrent venous thromboembolism during anticoagulation with edoxaban or warfarin: A post hoc analysis of the Hokusai-VTE trial Recurrent venous thromboembolism during anticoagulation with edoxaban or warfarin: A post hoc analysis of the Hokusai-VTE trial - PubMed This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features! Clipboard, Search History, and several other advanced features are temporarily unavailable. COVID-19 is an emerging (...) . Recurrent venous thromboembolism during anticoagulation with edoxaban or warfarin: A post hoc analysis of the Hokusai-VTE trial , , , , Affiliations Expand Affiliations 1 Dept. of Medicine I, Medical University of Vienna, Austria. Electronic address: sabine.eichinger@meduniwien.ac.at. 2 Daiichi-Sankyo Pharma Development, Basking Ridge, NJ, United States of America. 3 Dept. of Medicine I, Medical University of Vienna, Austria. PMID: 32750571 DOI: Item in Clipboard Recurrent venous thromboembolism during

2020 EvidenceUpdates

3. The Association between Oral Anticoagulants and Cancer Incidence among Individuals with Nonvalvular Atrial Fibrillation

The Association between Oral Anticoagulants and Cancer Incidence among Individuals with Nonvalvular Atrial Fibrillation The Association between Oral Anticoagulants and Cancer Incidence among Individuals with Nonvalvular Atrial Fibrillation - PubMed This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features! Clipboard, Search History, and several other advanced features are temporarily unavailable. COVID-19 is an emerging, rapidly evolving (...) Anticoagulants and Cancer Incidence among Individuals with Nonvalvular Atrial Fibrillation , , , , Affiliations Expand Affiliations 1 Centre for Clinical Epidemiology, Lady Davis Institute, Jewish General Hospital, Montreal, Quebec, Canada. 2 Department of Epidemiology, Biostatistics, and Occupational Health, McGill University, Montreal, Quebec, Canada. 3 Department of Neurology and Neurosurgery, McGill University, Montreal, Quebec, Canada. 4 Département de Médecine Générale, Université de Nantes, Nantes

2020 EvidenceUpdates

4. Should We Reintroduce Previous Venous Thromboembolism Into Decision-Making for Anticoagulation in Atrial Fibrillation?

Should We Reintroduce Previous Venous Thromboembolism Into Decision-Making for Anticoagulation in Atrial Fibrillation? Should We Reintroduce Previous Venous Thromboembolism Into Decision-Making for Anticoagulation in Atrial Fibrillation? - PubMed This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features! Clipboard, Search History, and several other advanced features are temporarily unavailable. COVID-19 is an emerging, rapidly evolving (...) We Reintroduce Previous Venous Thromboembolism Into Decision-Making for Anticoagulation in Atrial Fibrillation? , , , , , Affiliations Expand Affiliations 1 Aalborg Thrombosis Research Unit, Department of Clinical Medicine, Faculty of Health, Aalborg University, Denmark; Department of Medicine, North Denmark Regional Hospital, Hjørring, Denmark. Electronic address: t.overvad@rn.dk. 2 Aalborg Thrombosis Research Unit, Department of Clinical Medicine, Faculty of Health, Aalborg University, Denmark

2020 EvidenceUpdates

5. Direct oral anticoagulant versus low-molecular-weight heparin for treatment of venous thromboembolism in cancer patients: An updated meta-analysis of randomized controlled trials

Direct oral anticoagulant versus low-molecular-weight heparin for treatment of venous thromboembolism in cancer patients: An updated meta-analysis of randomized controlled trials Direct oral anticoagulant versus low-molecular-weight heparin for treatment of venous thromboembolism in cancer patients: An updated meta-analysis of randomized controlled trials - PubMed This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features! Clipboard, Search (...) Thromb Res Actions . 2020 Jun 18;194:57-65. doi: 10.1016/j.thromres.2020.06.025. Online ahead of print. Direct oral anticoagulant versus low-molecular-weight heparin for treatment of venous thromboembolism in cancer patients: An updated meta-analysis of randomized controlled trials , , , , , , , , Affiliations Expand Affiliations 1 Hurley Medical Center, Department of Internal Medicine, Flint, MI, USA; Michigan State University, College of Human Medicine, East Lansing, MI, USA. 2 Lebanese University

2020 EvidenceUpdates

6. Left Atrial Appendage Closure Versus Direct Oral Anticoagulants in High-Risk Patients With Atrial Fibrillation

Left Atrial Appendage Closure Versus Direct Oral Anticoagulants in High-Risk Patients With Atrial Fibrillation Left Atrial Appendage Closure Versus Direct Oral Anticoagulants in High-Risk Patients With Atrial Fibrillation - PubMed This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features! Clipboard, Search History, and several other advanced features are temporarily unavailable. COVID-19 is an emerging, rapidly evolving situation. Get (...) there aren't any new results Optional text in email: Save Cancel Create a file for external citation management software Create file Cancel Your RSS Feed Name of RSS Feed: Number of items displayed: Create RSS Cancel RSS Link Copy Actions Cite Share Permalink Copy Page navigation J Am Coll Cardiol Actions . 2020 Jun 30;75(25):3122-3135. doi: 10.1016/j.jacc.2020.04.067. Left Atrial Appendage Closure Versus Direct Oral Anticoagulants in High-Risk Patients With Atrial Fibrillation

2020 EvidenceUpdates

7. Management of Bleeding in Patients on Oral Anticoagulants

Management of Bleeding in Patients on Oral Anticoagulants EXPERT CONSENSUS DECISION PATHWAY 2020 ACC Expert Consensus Decision Pathway on Management of Bleeding in Patients on Oral Anticoagulants A Report of the American College of Cardiology Solution Set Oversight Committee Writing Committee* Gordon F. Tomaselli, MD, FACC, Chair Kenneth W. Mahaffey, MD, FACC, Vice Chair Adam Cuker, MD, MS Paul P. Dobesh, PHARMD John U. Doherty, MD, FACC John W. Eikelboom, MBBS Roberta Florido, MD, MHS Ty J (...) . OAC Reversal Agents in Development 608 5.7. Considerations for Restarting Anticoagulation.. 608 Figure 4. Considerations for Restarting Anticoagulation ..609 5.7.1. ShouldAnticoagulationBeRestarted? ..608 Table 6. Original Indications for Anti- coagulation With High Thrombotic Risk .. 610 5.7.2. Timing of Anticoagulation Reinitiation ..609 Figure 5. Restart of Anticoagulation 611 Figure 6. Delaying Restart of Anticoagulation . 612 5.7.2. Patient Engagement in Restarting Anticoagulation ... .. 610

2020 American College of Cardiology

8. Role of Combination Antiplatelet and Anticoagulation Therapy in Diabetes Mellitus and Cardiovascular Disease: Insights From the COMPASS Trial Full Text available with Trip Pro

Role of Combination Antiplatelet and Anticoagulation Therapy in Diabetes Mellitus and Cardiovascular Disease: Insights From the COMPASS Trial Role of Combination Antiplatelet and Anticoagulation Therapy in Diabetes Mellitus and Cardiovascular Disease: Insights From the COMPASS Trial - PubMed This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features! Clipboard, Search History, and several other advanced features are temporarily unavailable (...) Your RSS Feed Name of RSS Feed: Number of items displayed: Create RSS Cancel RSS Link Copy Actions Cite Share Permalink Copy Page navigation Circulation Actions . 2020 Jun 9;141(23):1841-1854. doi: 10.1161/CIRCULATIONAHA.120.046448. Epub 2020 Mar 28. Role of Combination Antiplatelet and Anticoagulation Therapy in Diabetes Mellitus and Cardiovascular Disease: Insights From the COMPASS Trial , , , , , , , , , , , , , , , , , , , , Collaborators, Affiliations Expand Collaborators COMPASS Steering

2020 EvidenceUpdates

9. Direct Oral Anticoagulants for the Treatment of Acute Venous Thromboembolism Associated with Cancer: A Systematic Review and Meta-Analysis Full Text available with Trip Pro

Direct Oral Anticoagulants for the Treatment of Acute Venous Thromboembolism Associated with Cancer: A Systematic Review and Meta-Analysis Direct Oral Anticoagulants for the Treatment of Acute Venous Thromboembolism Associated with Cancer: A Systematic Review and Meta-Analysis - PubMed This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features! Clipboard, Search History, and several other advanced features are temporarily unavailable (...) Your RSS Feed Name of RSS Feed: Number of items displayed: Create RSS Cancel RSS Link Copy Actions Cite Share Permalink Copy Page navigation Thromb Haemost Actions . 2020 Jul;120(7):1128-1136. doi: 10.1055/s-0040-1712098. Epub 2020 May 4. Direct Oral Anticoagulants for the Treatment of Acute Venous Thromboembolism Associated with Cancer: A Systematic Review and Meta-Analysis , , , , , , , , , , , Affiliations Expand Affiliations 1 Internal Vascular and Emergency Medicine - Stroke Unit, University

2020 EvidenceUpdates

10. Direct-acting oral anticoagulants (DOACs): reminder of bleeding risk, including availability of reversal agents

Direct-acting oral anticoagulants (DOACs): reminder of bleeding risk, including availability of reversal agents Direct-acting oral anticoagulants (DOACs): reminder of bleeding risk, including availability of reversal agents - GOV.UK Tell us whether you accept cookies We use about how you use GOV.UK. We use this information to make the website work as well as possible and improve government services. Accept all cookies You’ve accepted all cookies. You can at any time. Hide Search Guidance (...) and support Direct-acting oral anticoagulants (DOACs): reminder of bleeding risk, including availability of reversal agents Remain vigilant for signs and symptoms of bleeding complications during treatment with DOACs (apixaban, dabigatran, edoxaban, rivaroxaban), especially in patients with increased bleeding risks. Specific reversal agents are available for dabigatran (Praxbind▼, idarucizumab), and apixaban and rivaroxaban (Ondexxya▼, andexanet alfa). Published 29 June 2020 From: Therapeutic area

2020 MHRA Drug Safety Update

11. Use of Anticoagulation in Patients with COVID-19 Infection Full Text available with Trip Pro

Use of Anticoagulation in Patients with COVID-19 Infection Use of Anticoagulation in Patients with COVID-19 Infection - CanadiEM Use of Anticoagulation in Patients with COVID-19 Infection In by Johnny Huang June 18, 2020 Introduction The novel coronavirus, known as COVID-19, was originally reported in a cluster of pneumonia cases in Wuhan (China) near the end of 2019 ​1​ . Over the next 6 months, COVID-19 has emerged as the world’s newest pandemic disease with over 7 million cases worldwide ​1 (...) and reduced fibrinogen levels, the distinguishing feature of COVID-19 pertains to thrombosis formation and inflammation without significant consumption of coagulation markers ​5​ . A case-series study showed an increased risk for VTE, mostly pulmonary embolism, among intensive care unit (ICU) patients with COVID-19-associated acute respiratory distress syndrome (ARDS) than those with non-COVID-19 ARDS, despite being on prophylactic anticoagulation ​9​ . Similar studies showed an incidence of VTE up to 30

2020 CandiEM

12. Quality of life after switching from well-controlled vitamin K antagonist to direct oral anticoagulant: Little to GAInN Full Text available with Trip Pro

Quality of life after switching from well-controlled vitamin K antagonist to direct oral anticoagulant: Little to GAInN Quality of Life After Switching From Well-Controlled Vitamin K Antagonist to Direct Oral Anticoagulant: Little to GAInN - PubMed This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features! Clipboard, Search History, and several other advanced features are temporarily unavailable. National Institutes of Health National (...) : Number of items displayed: Create RSS Cancel RSS Link Copy Actions Cite Share Permalink Copy Page navigation Thromb Res Actions . 2020 Jun;190:69-75. doi: 10.1016/j.thromres.2020.04.007. Epub 2020 Apr 14. Quality of Life After Switching From Well-Controlled Vitamin K Antagonist to Direct Oral Anticoagulant: Little to GAInN , , , , , Affiliations Expand Affiliations 1 Department of Hematology, University of Groningen, University Medical Center Groningen, Groningen, the Netherlands; Certe Thrombosis

2020 EvidenceUpdates

13. Psychotropic Drugs and Outcome in Patients Receiving Anticoagulant Therapy for Venous Thromboembolism

Psychotropic Drugs and Outcome in Patients Receiving Anticoagulant Therapy for Venous Thromboembolism Psychotropic Drugs and Outcome in Patients Receiving Anticoagulant Therapy for Venous Thromboembolism - PubMed This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features! Clipboard, Search History, and several other advanced features are temporarily unavailable. National Institutes of Health National Library of Medicine National Center (...) Link Copy Actions Cite Share Permalink Copy Page navigation Thromb Haemost Actions . 2020 Apr;120(4):620-626. doi: 10.1055/s-0040-1708482. Epub 2020 Apr 14. Psychotropic Drugs and Outcome in Patients Receiving Anticoagulant Therapy for Venous Thromboembolism , , , , , , , , , , Affiliations Expand Affiliations 1 Department of Internal Medicine and Emergency, Parc Sanitari Sant Joan de Déu-Hospital General, Barcelona, Spain. 2 Department of Haematology and Bone Marrow Transplantation, Rambam Health

2020 EvidenceUpdates

14. Meta-Analysis Comparing Direct Oral Anticoagulants Versus Warfarin in Morbidly Obese Patients With Atrial Fibrillation

Meta-Analysis Comparing Direct Oral Anticoagulants Versus Warfarin in Morbidly Obese Patients With Atrial Fibrillation Meta-Analysis Comparing Direct Oral Anticoagulants Versus Warfarin in Morbidly Obese Patients With Atrial Fibrillation - PubMed This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features! Clipboard, Search History, and several other advanced features are temporarily unavailable. National Institutes of Health National Library (...) displayed: Create RSS Cancel RSS Link Copy Actions Cite Share Permalink Copy Page navigation Am J Cardiol Actions . 2020 Jul 1;126:23-28. doi: 10.1016/j.amjcard.2020.03.048. Epub 2020 Apr 8. Meta-Analysis Comparing Direct Oral Anticoagulants Versus Warfarin in Morbidly Obese Patients With Atrial Fibrillation , , , Affiliations Expand Affiliations 1 Department of Clinical Pharmacy, West Virginia University School of Pharmacy, Morgantown, West Virginia. Electronic address: kazuhiko.kido0322@gmail.com. 2

2020 EvidenceUpdates

15. The Effect of Warfarin Administration Time on Anticoagulation Stability (INRange): A Pragmatic Randomized Controlled Trial Full Text available with Trip Pro

The Effect of Warfarin Administration Time on Anticoagulation Stability (INRange): A Pragmatic Randomized Controlled Trial The Effect of Warfarin Administration Time on Anticoagulation Stability (INRange): A Pragmatic Randomized Controlled Trial - PubMed This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features! Clipboard, Search History, and several other advanced features are temporarily unavailable. National Institutes of Health National (...) Permalink Copy Page navigation Ann Fam Med Actions . 2020 Jan;18(1):42-49. doi: 10.1370/afm.2488. The Effect of Warfarin Administration Time on Anticoagulation Stability (INRange): A Pragmatic Randomized Controlled Trial , , , , , , , Affiliations Expand Affiliations 1 Department of Family Medicine, University of Alberta, Edmonton, Alberta, Canada scott.garrison@ualberta.ca. 2 Department of Family Medicine, University of Alberta, Edmonton, Alberta, Canada. 3 Department of Anesthesiology, Pharmacology

2020 EvidenceUpdates

16. Comparing Major Bleeding Risk in Outpatients With Atrial Fibrillation or Flutter by Oral Anticoagulant Type (from the National Cardiovascular Disease Registry`s Practice Innovation and Clinical Excellence Registry)

Comparing Major Bleeding Risk in Outpatients With Atrial Fibrillation or Flutter by Oral Anticoagulant Type (from the National Cardiovascular Disease Registry`s Practice Innovation and Clinical Excellence Registry) Comparing Major Bleeding Risk in Outpatients With Atrial Fibrillation or Flutter by Oral Anticoagulant Type (From the National Cardiovascular Disease Registry's Practice Innovation and Clinical Excellence Registry) - PubMed This site needs JavaScript to work properly. Please enable (...) when there aren't any new results Optional text in email: Save Cancel Create a file for external citation management software Create file Cancel Actions Cite Share Permalink Copy Page navigation Am J Cardiol Actions . 2020 May 15;125(10):1500-1507. doi: 10.1016/j.amjcard.2020.02.028. Epub 2020 Mar 5. Comparing Major Bleeding Risk in Outpatients With Atrial Fibrillation or Flutter by Oral Anticoagulant Type (From the National Cardiovascular Disease Registry's Practice Innovation and Clinical

2020 EvidenceUpdates

17. Anticoagulation with or without Clopidogrel after Transcatheter Aortic-Valve Implantation. (Abstract)

Anticoagulation with or without Clopidogrel after Transcatheter Aortic-Valve Implantation. The roles of anticoagulation alone or with an antiplatelet agent after transcatheter aortic-valve implantation (TAVI) have not been well studied.We performed a randomized trial of clopidogrel in patients undergoing TAVI who were receiving oral anticoagulation for appropriate indications. Patients were assigned before TAVI in a 1:1 ratio not to receive clopidogrel or to receive clopidogrel for 3 months (...) from cardiovascular causes, ischemic stroke, or myocardial infarction (secondary composite 2), both tested for noninferiority (noninferiority margin, 7.5 percentage points) and superiority.Bleeding occurred in 34 of the 157 patients (21.7%) receiving oral anticoagulation alone and in 54 of the 156 (34.6%) receiving oral anticoagulation plus clopidogrel (risk ratio, 0.63; 95% confidence interval [CI], 0.43 to 0.90; P = 0.01); most bleeding events were at the TAVI access site. Non-procedure-related

2020 NEJM

18. Covid-19: Clinical guide for the management of anticoagulant services during the coronavirus pandemic

Covid-19: Clinical guide for the management of anticoagulant services during the coronavirus pandemic Publications approval reference: 001559 NHS England and NHS Improvement Specialty guides for patient management during the coronavirus pandemic Clinical guide for the management of anticoagulant services during the coronavirus pandemic 31 March 2020 Version 1 As healthcare professionals we all have general responsibilities in relation to coronavirus and for these we should seek and act (...) on national and local guidelines. We also have a specific responsibility to ensure that anticoagulant care continues with the minimum burden on the NHS. We must engage with management and clinical teams planning the local response in our hospitals and across primary care. Anticoagulant services may not seem to be in the frontline with coronavirus but we do have a key role in continuing to keep patients on anticoagulants as safe as possible; this must be planned. In response to pressures on the NHS

2020 NHS England

19. Options for Peripartum Anticoagulation in Areas Affected by Shortage of Unfractionated Heparin

Options for Peripartum Anticoagulation in Areas Affected by Shortage of Unfractionated Heparin Options for Peripartum Anticoagulation in Areas Affected by Shortage of Unfractionated Heparin | ACOG Clinical Guidance Journals & Publications Patient Education Topics Featured Clinical Topics Hi, Featured Clinical Topics Clinical Guidance Options for Peripartum Anticoagulation in Areas Affected by Shortage of Unfractionated Heparin March 2020 Jump to Resources Share By reading this page you agree (...) to ACOG's Terms and Conditions. . Baxter Healthcare first reported to the U.S. Food and Drug Administration in November 2017 shortages of heparin sodium 2,000 international units/L in 0.9% weight/volume sodium chloride intravenous infusion, heparin sodium 2,000 USP units in 1,000 mL, and heparin sodium 1,000 USP units in 500 mL . The purpose of this practice advisory is to review options for anticoagulation in late gestation for practitioners in areas affected by a heparin shortage. In some cases

2020 American College of Obstetricians and Gynecologists

20. Equivalent inpatient mortality among direct-acting oral anticoagulant and warfarin users presenting with major hemorrhage Full Text available with Trip Pro

Equivalent inpatient mortality among direct-acting oral anticoagulant and warfarin users presenting with major hemorrhage Extrapolation of clinical trial results comparing warfarin and direct-acting oral anticoagulant (DOAC) users experiencing major hemorrhage to clinical care is challenging due to differences seen among non-randomized oral anticoagulant users, bleed location, and etiology. We hypothesized that inpatient all-cause-mortality among patients presenting with major hemorrhage (...) differed based on the home-administered anticoagulant medication class, DOAC versus warfarin.More than 1.5 million hospitalizations were screened and 3731 patients with major hemorrhage were identified in the REDS-III Recipient Database. Propensity score matching and stratification were used to account for potentially confounding factors.Inpatient all-cause-mortality was lower for DOAC (HR = 0.60, 95%CI 0.45-0.80, p = 0.0005) before accounting for confounding and competing events. Inpatient all-cause

2020 EvidenceUpdates